Impact of <i>Haemophilus influenzae</i> type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes

Salam, Rehana A; Das, Jai K; Soeandy, Chesarahmia Dojo; Lassi, Zohra S; Bhutta, Zulfiqar A

doi:10.1002/14651858.cd009982.pub2

Cited by 19 publications

(18 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19,20 Moreover, the interruption of influenza virus transmission by vaccinating the mother, together with transplacental transfer of vaccine-associated antibody, also reduces the risk of infection for infants 3-4 months old (before direct vaccination is possible). 21 Despite the heightened risk of influenza illness in pregnant women and benefits of vaccination, vaccination coverage rates in this population remain suboptimal. In recent years, coverage rates in the United States and Australia have ranged from 20%-50%.…”

Section: Introductionmentioning

confidence: 99%

“…(vi) References of studies included in each analysis Previous reviews of antenatal influenza vaccination have reported limited and mixed evidence on the association between influenza vaccination, influenza infection and adverse birth outcomes, and have not examined the relationship between vaccination timing and immunogenicity. 21,[27][28][29][30][31][32] This systematic review examined whether the timing of influenza vaccination during pregnancy affects the immunogenicity of the vaccine in the mother and transplacental transfer of antibody to the newborn.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal timing of influenza vaccine during pregnancy: A systematic review and meta‐analysis

Cuningham

Geard

Fielding

et al. 2019

Influenza Resp Viruses

View full text Add to dashboard Cite

Background Pregnant women have an elevated risk of illness and hospitalisation from influenza. Pregnant women are recommended to be prioritised for influenza vaccination during any stage of pregnancy. The risk of seasonal influenza varies substantially throughout the year in temperate climates; however, there is limited knowledge of how vaccination timing during pregnancy impacts the benefits received by the mother and foetus. Objectives To compare antenatal vaccination timing with regard to influenza vaccine immunogenicity during pregnancy and transplacental transfer to their newborns. Methods Studies were eligible for inclusion if immunogenicity to influenza vaccine was evaluated in women stratified by trimester of pregnancy. Haemagglutination inhibition (HI) titres, stratified by trimester of vaccination, had to be measured at either pre‐vaccination and within one month post‐vaccination, post‐vaccination and at delivery in the mother, or in cord/newborn blood. Authors searched PubMed, Scopus, Web of Science and EMBASE databases from inception until June 2016 and authors of identified studies were contacted for additional data. Extracted data were tabulated and summarised via random‐effect meta‐analyses and qualitative methods. Results Sixteen studies met the inclusion criteria. Meta‐analyses found that compared with women vaccinated in an earlier trimester, those vaccinated in a later trimester had a greater fold increase in HI titres (1.33‐ to 1.96‐fold) and higher HI titres in cord/newborn blood (1.21‐ to 1.64‐fold). Conclusions This review provides comparative analysis of the effect of vaccination timing on maternal immunogenicity and protection of the infant that is informative and relevant to current vaccine scheduling for pregnant women.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Optimal timing of influenza vaccine during pregnancy: A systematic review and meta‐analysis

Cuningham

Geard

Fielding

et al. 2019

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…The Canadian National Advisory Committee on Immunization (NACI) and World Health Organization (WHO) recommend influenza immunization during pregnancy to reduce the risk of severe infection in pregnancy and early infancy (1,3). The safety of influenza immunization in pregnancy has been demonstrated in numerous studies and summarized in several systematic reviews (3)(4)(5)(6). Based on systematic reviews, including a review by the WHO Global Advisory Committee on Vaccine Safety (3), inactivated influenza vaccines (IIVs) demonstrated no increased risk of adverse outcomes, such as spontaneous abortion, stillbirth or congenital anomalies.…”

Section: Introductionmentioning

confidence: 99%

“…The product monograph text is developed by the vaccine manufacturers with input and authorization from Health Canada, the National Regulatory Authority (NRA). Health Canada reviews safety and effectiveness data presented by the manufacturer that is generally limited to product-specific data from randomized clinical trials; however, few clinical trials on IIVs have been conducted in pregnant women (6). Consequently, product monograph language may appear more cautionary than NACI recommendations (e.g., "use only following the advice of a health care professional, based on consideration of the benefits and risks to the mother and the foetus", FluLaval ® , GlaxoSmithKline, Sainte-Foy, Québec) (10).…”

Section: Introductionmentioning

confidence: 99%

Do health care providers trust product monograph information regarding use of vaccines in pregnancy? A qualitative study

Top

Arkell

Graham

et al. 2018

CCDR

View full text Add to dashboard Cite

Background: Influenza immunization is recommended in pregnancy to prevent severe infections in pregnant women and newborns, yet vaccine uptake remains low. Studies suggest that cautionary language in vaccine product monographs regarding safety and use in pregnancy affects health care providers' perceptions of vaccine safety and how they counsel pregnant women. Objective: To conduct a qualitative analysis of health care provider perceptions of the safety of inactivated influenza vaccines and their recommendations for use in pregnancy based on product monograph language statements. Methods: Health care providers were recruited at two international health conferences and from teaching programs in Ethiopia, Ghana, Uganda, and Laos during September and October 2015. After reading the product monograph excerpts for three licensed inactivated influenza vaccines, participants completed a ten-item online survey with quantitative and qualitative components that captured perceptions of vaccine safety. Results: Health care providers identified a lack of trust in manufacturers' and product monograph information. They perceived product monograph language as ambiguous and not "up-to-date" with current evidence. Health care providers wanted product monograph language that clearly conveyed evidence for the risks and benefits of the vaccine in an understandable manner. Conclusion: This study suggests that adopting best practices in the wording of product monographs would help to support evidence-based use of vaccines in pregnant women.

show abstract

“…Les fournisseurs de soins de santé font-ils confiance aux renseignements contenus dans les monographies de produit relativement à l'utilisation des vaccins chez les femmes enceintes? Une étude qualitative KA Top 1,2 *, C Arkell 3 , JE Graham 1,2 , H Scott 4 , SA McNeil 2,5 , J Mannerfeldt 6 , NE MacDonald 1,2 Résumé Contexte : La vaccination contre la grippe est recommandée pendant la grossesse pour prévenir les infections graves chez les femmes enceintes et les nouveau-nés, mais les vaccins restent peu utilisés dans ces cas. Des études semblent indiquer que les mises en garde sur l'innocuité et l'utilisation des vaccins chez les femmes enceintes stipulées dans les monographies de produits influent sur la perception des fournisseurs de soins de santé quant à l'innocuité des vaccins et sur les conseils qu'ils donnent aux femmes enceintes.…”

unclassified

Les fournisseurs de soins de santé font-ils confiance aux renseignements contenus dans les monographies de produit relativement à l'utilisation des vaccins chez les femmes enceintes? Une étude qualitative

Top¹,

Arkell²,

Graham³

et al. 2018

RMTC

View full text Add to dashboard Cite

Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes

Cited by 19 publications

References 41 publications

Optimal timing of influenza vaccine during pregnancy: A systematic review and meta‐analysis

Optimal timing of influenza vaccine during pregnancy: A systematic review and meta‐analysis

Do health care providers trust product monograph information regarding use of vaccines in pregnancy? A qualitative study

Les fournisseurs de soins de santé font-ils confiance aux renseignements contenus dans les monographies de produit relativement à l'utilisation des vaccins chez les femmes enceintes? Une étude qualitative

Contact Info

Product

Resources

About